FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR

FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR

The present invention relates to a formulation optimized for a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor and, more specifically, to an aqueous pharmaceutical formulation having a pH of 6.0-7.0, comprising a fusion protein dimer that compris...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KWON, Soontak, CHO, Young-Gyu, JANG, Myung Ho
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator KWON, Soontak
CHO, Young-Gyu
JANG, Myung Ho
description The present invention relates to a formulation optimized for a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor and, more specifically, to an aqueous pharmaceutical formulation having a pH of 6.0-7.0, comprising a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and Poloxamer 188. The fusion protein present in the formulation according to the present invention is contained at a high concentration, has improved stability and thus can be easily administered through subcutaneous injection, and has excellent IgE-binding capacity as compared to existing therapeutic agents comprising an anti-IgE antibody, and thus can be usefully utilized in an injection for treating an IgE-mediated allergic disease.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2022232566A9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2022232566A9</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2022232566A93</originalsourceid><addsrcrecordid>eNqNi0EKwjAQRbNxIeodBlwLkmLB5ZhO2oE0CWkC7mqRuBIt1PujFQ_g6j8e7y_FRbvQJoORnQWnQaduJh9cJLbAVplUsa2BzjGgImM-cYDKtcjfAxrfIHTplCzHWXBNoBUEUuSjC2uxuA33KW9-uxJbTVE1uzw--zyNwzU_8qvHJPdSykIeyhKPxX_VG160NEY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><source>esp@cenet</source><creator>KWON, Soontak ; CHO, Young-Gyu ; JANG, Myung Ho</creator><creatorcontrib>KWON, Soontak ; CHO, Young-Gyu ; JANG, Myung Ho</creatorcontrib><description>The present invention relates to a formulation optimized for a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor and, more specifically, to an aqueous pharmaceutical formulation having a pH of 6.0-7.0, comprising a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and Poloxamer 188. The fusion protein present in the formulation according to the present invention is contained at a high concentration, has improved stability and thus can be easily administered through subcutaneous injection, and has excellent IgE-binding capacity as compared to existing therapeutic agents comprising an anti-IgE antibody, and thus can be usefully utilized in an injection for treating an IgE-mediated allergic disease.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240516&amp;DB=EPODOC&amp;CC=AU&amp;NR=2022232566A9$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240516&amp;DB=EPODOC&amp;CC=AU&amp;NR=2022232566A9$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KWON, Soontak</creatorcontrib><creatorcontrib>CHO, Young-Gyu</creatorcontrib><creatorcontrib>JANG, Myung Ho</creatorcontrib><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><description>The present invention relates to a formulation optimized for a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor and, more specifically, to an aqueous pharmaceutical formulation having a pH of 6.0-7.0, comprising a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and Poloxamer 188. The fusion protein present in the formulation according to the present invention is contained at a high concentration, has improved stability and thus can be easily administered through subcutaneous injection, and has excellent IgE-binding capacity as compared to existing therapeutic agents comprising an anti-IgE antibody, and thus can be usefully utilized in an injection for treating an IgE-mediated allergic disease.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi0EKwjAQRbNxIeodBlwLkmLB5ZhO2oE0CWkC7mqRuBIt1PujFQ_g6j8e7y_FRbvQJoORnQWnQaduJh9cJLbAVplUsa2BzjGgImM-cYDKtcjfAxrfIHTplCzHWXBNoBUEUuSjC2uxuA33KW9-uxJbTVE1uzw--zyNwzU_8qvHJPdSykIeyhKPxX_VG160NEY</recordid><startdate>20240516</startdate><enddate>20240516</enddate><creator>KWON, Soontak</creator><creator>CHO, Young-Gyu</creator><creator>JANG, Myung Ho</creator><scope>EVB</scope></search><sort><creationdate>20240516</creationdate><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><author>KWON, Soontak ; CHO, Young-Gyu ; JANG, Myung Ho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2022232566A93</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KWON, Soontak</creatorcontrib><creatorcontrib>CHO, Young-Gyu</creatorcontrib><creatorcontrib>JANG, Myung Ho</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KWON, Soontak</au><au>CHO, Young-Gyu</au><au>JANG, Myung Ho</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR</title><date>2024-05-16</date><risdate>2024</risdate><abstract>The present invention relates to a formulation optimized for a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor and, more specifically, to an aqueous pharmaceutical formulation having a pH of 6.0-7.0, comprising a fusion protein dimer that comprises an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and Poloxamer 188. The fusion protein present in the formulation according to the present invention is contained at a high concentration, has improved stability and thus can be easily administered through subcutaneous injection, and has excellent IgE-binding capacity as compared to existing therapeutic agents comprising an anti-IgE antibody, and thus can be usefully utilized in an injection for treating an IgE-mediated allergic disease.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2022232566A9
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A17%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KWON,%20Soontak&rft.date=2024-05-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2022232566A9%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true